The platform enables direct, unbiased genome-wide identification and quantification of the exact position of double strand DNA breaks in edited cells.

Prime Medicine, Inc. faces risks in the gene editing sector despite positive developments, caution advised for retail investors. Click for my PRME stock update.

International collaborations, refined gene-editing protocols, and targeted immunologic maneuvers keep the cancer gene therapy ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

Beware the rise of ‘Marxist nationalism’. As Australian ex-PM Kevin Rudd explains in his new study, On Xi Jinping, China has imperial dreams ...

Precision BioSciences, Inc. , a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene ...

Financial writer discusses MGX's gene editing technology, cash runway, and lack of clinical data for potential future ...

Welcome to the 2025 Imagine 2200: Climate Fiction for Future Ancestors collection. For four years, this contest has celebrated stories that invite us to imagine the future we want — futures in ...

The immense variation in the amount of DNA contained in the cells of organisms has long fascinated scientists. Known as the genome size (GS), or C-value of a species, the amount of DNA in one entire ...

Genome India project: The Department of Biotechnology recently announced its new platform and framework for sharing its 10,000 human genome dataset. The sequences of healthy individuals — from 99 ...